Show simple item record

dc.contributor.authorNguyen, Thi Van Anh
dc.contributor.authorAnthony, Richard M
dc.contributor.authorBañuls, Anne-Laure
dc.contributor.authorVu, Dinh Hoa
dc.contributor.authorAlffenaar, Jan-Willem C
dc.date.accessioned2018-03-08T11:12:53Z
dc.date.available2018-03-08T11:12:53Z
dc.date.issued2017-11-08
dc.identifier.citationBedaquiline resistance: Its emergence, mechanism and prevention. 2017 Clin. Infect. Dis.en
dc.identifier.issn1537-6591
dc.identifier.pmid29126225
dc.identifier.doi10.1093/cid/cix992
dc.identifier.urihttp://hdl.handle.net/10029/621555
dc.description.abstractBedaquiline, a new anti-tuberculosis drug, has already been used in more than 50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This paper aims to review currently identified mechanisms of resistance, the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from the compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678 and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed.Understanding any target and non-target based mechanisms is essential to minimize the resistance development and treatment failure, help to develop appropriate DST for bedaquiline and genetic based resistance screening.
dc.language.isoenen
dc.rightsinfo:eu-repo/semantics/closedAccessen
dc.titleBedaquiline resistance: Its emergence, mechanism and prevention.en
dc.typeArticleen
dc.identifier.journalClin Infect Dis 2018; 66(10):1625-30en
html.description.abstractBedaquiline, a new anti-tuberculosis drug, has already been used in more than 50 countries. The emergence of bedaquiline resistance is alarming, as it may result in the rapid loss of this new drug. This paper aims to review currently identified mechanisms of resistance, the emergence of bedaquiline resistance, and discuss strategies to delay the resistance acquisition. In vitro and clinical studies as well as reports from the compassionate use have identified the threat of bedaquiline resistance and cross-resistance with clofazimine, emphasizing the crucial need for the systematic surveillance of resistance. Currently known mechanisms of resistance include mutations within the atpE, Rv0678 and pepQ genes. The development of standardized drug susceptibility testing (DST) for bedaquiline is urgently needed.Understanding any target and non-target based mechanisms is essential to minimize the resistance development and treatment failure, help to develop appropriate DST for bedaquiline and genetic based resistance screening.


This item appears in the following Collection(s)

Show simple item record